Abstract
Traumatic injury is a significant cause of morbidity and mortality in the United States. Massive hemorrhage is responsible for the vast majority of deaths. Evolution in trauma treatment has resulted in major improvements to emergency care. Tranexamic acid (TXA), an antifibrinolytic agent, is synthetically derived from amino acids. The CRASH-2 study demonstrated that the early administration of TXA results in significant decreases in morbidity and mortality. Experiences by coalition forces in Southwest Asia found a substantial increase in survival of trauma patients with early TXA administration. The PAMPer trial has demonstrated the success of taking plasma to the scene of the incident by helicopter; TXA offers additional benefits when transported by the same means. Air medical utilization of TXA can take battlefield trauma care to the scene of civilian traumatic injuries and save lives.